Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BHE202212

Reversible MAOB Inhibitor

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: Reversible MAOB Inhibitor
    Indications: Parkinson's disease
    Research phase: Phase 1 was completed in China, and IP has been granted in the US
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MOA




    (1) Monoamine oxidase-B (MAOB) is an enzyme in the body that breaks down several chemicals in the brain, including DA.


    (2) An MAOB inhibitor makes more DA available to the brain. When used with other medications, It can improve many PD movement symptoms and reduce motor fluctuations-minimizing off time and extending on time.


    2. High selectivity and inhibitory activity.




    3. Potential global first "Forth-generation MAOB inhibitor".



    4. Better treatment effect for PD than Safinamide in preclinical.


    (1) pre-MPTP administration: Improve the physical activity of mice, increase the concentration of DA in the striatum, and protect dopaminergic neurons in substantia nigra compacta.


    (2) post-MPTP administration: In combination with L-dopa/Bens, the concentration of DA in the striatum is significantly increased and the therapeutic effect on PD is enhanced.


    (3) Low risk of heart disease, reduce the phenomenon of mandibular tremor induced by Galanthamine.


    5. Excellent phase 1 data.


    (1) PK: Fast absorption, medium elimination speed, No Cmax and litter AUC accumulation after multiple administrations.


    (2) Medication safety, well-tolerated, no AEs (CTCAE ≥ 3), no sAEs.

  • Project Introduction

    1. Asset type: Reversible MAOB Inhibitor

    2. Indication: Parkinson's disease

    3. Modality: Small molecular

    4. Research phase: Phase 1 was completed in China, and IP has been granted in the US

    5. Cooperation demands: License-out or co-development

    6. Research progress:

    (1) Phase 1 trial is completed.
    (2) Safety, well-tolerated, no AEs (CTCAE ≥ 3), no sAEs.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message